| Schedule of options granted to non-executive directors under the Adaptimmune Therapeutics plc 2015 Share Option Scheme |
|
|
|
|
|
|
Options granted to non-executive directors on May 11, 2015: |
|
Immediately on grant date |
Options granted to a non-executive director on June 23, 2016: |
|
25% on the first anniversary of the grant date and 75% in monthly installments over the following two years |
Options granted to non-executive directors on August 11, 2016: |
|
100% on the first anniversary of the grant date |
Options granted to non-executive directors on November 28, 2016: |
|
25% on the first anniversary of the grant date and 75% in monthly installments over the following two years |
Options granted to non-executive directors on July 3, 2017 |
|
100% on the first anniversary of the grant date |
Options granted to non-executive directors on June 22, 2018: |
|
100% on the first anniversary of the grant date |
Options granted to a non-executive director on July 5, 2018: |
|
25% on the first anniversary of the grant date and 75% in monthly instalments over the following two years |
Options granted to non-executive directors on July 2, 2019: |
|
100% on the first anniversary of the grant date |
|
| Summary of all stock option activity |
|
|
|
|
|
|
|
|
|
|
Year ended |
|
|
December 31, |
|
|
2019 |
|
2018 |
|
Number of options over ordinary shares granted |
|
|
15,679,383 |
|
|
20,771,970 |
|
Weighted average fair value of ordinary shares options |
|
$ |
0.48 |
|
$ |
0.87 |
|
Number of RSU-style options granted |
|
|
8,020,410 |
|
|
8,603,676 |
|
Weighted average fair value of RSU-style options granted |
|
$ |
0.86 |
|
$ |
1.37 |
|
The following table summarizes all stock option activity for the year ended December 31, 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
Average |
|
|
|
|
|
|
|
average |
|
remaining |
|
Aggregate |
|
|
|
|
exercise price |
|
contractual |
|
intrinsic value |
|
|
Options |
|
per option |
|
term (years) |
|
(thousands) |
Outstanding at January 1, 2019 |
|
87,564,719 |
|
£ |
0.60 |
|
|
|
|
|
Changes during the period: |
|
|
|
|
|
|
|
|
|
|
Granted |
|
23,699,793 |
|
£ |
0.41 |
|
|
|
|
|
Exercised |
|
(3,549,298) |
|
£ |
0.08 |
|
|
|
|
|
Forfeited |
|
(18,837,142) |
|
£ |
0.60 |
|
|
|
|
|
Outstanding at December 31, 2019 |
|
88,878,072 |
|
£ |
0.57 |
|
6.8 |
|
£ |
1,991 |
Exercisable at December 31, 2019 |
|
51,953,196 |
|
£ |
0.63 |
|
5.6 |
|
£ |
263 |
The following table summarizes information about stock options granted based on the market value at grant date which were outstanding as of December 31, 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
Average |
|
|
|
|
|
|
|
average |
|
remaining |
|
Aggregate |
|
|
|
|
exercise price |
|
contractual |
|
intrinsic value |
|
|
Options |
|
per option |
|
term (years) |
|
(thousands) |
Outstanding at January 1, 2019 |
|
79,465,357 |
|
£ |
0.66 |
|
|
|
|
|
Changes during the period: |
|
|
|
|
|
|
|
|
|
|
Granted |
|
15,679,383 |
|
£ |
0.62 |
|
|
|
|
|
Exercised |
|
(2,406,298) |
|
£ |
0.12 |
|
|
|
|
|
Forfeited |
|
(16,092,106) |
|
£ |
0.70 |
|
|
|
|
|
Outstanding at December 31, 2019 |
|
76,646,336 |
|
£ |
0.66 |
|
6.5 |
|
£ |
139 |
Exercisable at December 31, 2019 |
|
51,137,121 |
|
£ |
0.64 |
|
5.6 |
|
£ |
139 |
The following table summarizes information about options which have a nominal exercise price (similar to restricted stock units (RSUs)) which were outstanding as of December 31, 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
remaining |
|
Aggregate |
|
|
|
|
|
contractual |
|
intrinsic value |
|
|
Options |
|
|
term (years) |
|
(thousands) |
Outstanding at January 1, 2019 |
|
8,099,362 |
|
|
|
|
|
|
Changes during the period: |
|
|
|
|
|
|
|
|
Granted |
|
8,020,410 |
|
|
|
|
|
|
Exercised |
|
(1,143,000) |
|
|
|
|
|
|
Forfeited |
|
(2,745,036) |
|
|
|
|
|
|
Outstanding at December 31, 2019 |
|
12,231,736 |
|
|
8.7 |
|
£ |
1,851 |
Exercisable at December 31, 2019 |
|
816,075 |
|
|
8.0 |
|
£ |
124 |
|